World Vaccine Congress Washington 2026

Richard Hughes, Spreeha Choudhury, Will Walters, and Anna Larson speak at the World Vaccine Congress, which runs from March 30 to April 2.

On March 30, Anna moderates a panel discussion, "How Vaccine Access Differs Across Countries—and What to Do About It," as part of the Global Health Workshop. Topics include:

• Examine how systems shape vaccine access from development to delivery.
• Contrast vaccine pathways in high- vs. low- and middle-income countries.
• Highlight barriers like trial investment gaps and delayed approvals.
• Share strategies from global experts to improve equitable access.

On April 1, Richard joins a panel discussion titled "Prove It's Safe: Is This the New Vaccine Policy ‘Norm?’" Session description:

The traditional vaccine policy infrastructure in flux—most notably emerging guidance from FDA, disruption of long-standing ACIP processes, and threats to the vaccine injury compensation system— this panel will discuss these changes and their implications for vaccine access, healthy vaccine markets, and innovation. How do we best respond to these changes and how do we most effectively communicate to a confused public?

Topic include:

• Strategies for maintaining scientific integrity and public confidence in a fragmented system.
• The importance of medical societies in developing evidence-based vaccine recommendations.
• The role of new organizations (EVAT: Expert Vaccine Analysis Team and VIP: Vaccine Integrity Project) as independent sources of vaccine science
• An assessment of the health of vaccine markets and the future of innovation
• Emerging legal threats for providers and manufacturers

Also on April 1, Spreeha speaks on a panel titled "The Crucial Role of Tone: Sustaining High Vaccine Uptake Through Effective Public Health Messaging Vaccine Access." Topics include:

• Public health messaging tone is crucial, even in pro-vaccine areas.
• Focus on proactive misinformation prevention and effective message framing.
• Emphasizes maintaining strong community partnerships.
• Shares best practices from high-uptake areas to inform low-uptake strategies

On April 2, Will co-presents "How Manufacturers Are Responding to Decreasing Public Trust in Vaccines and Science." Topics include:

• Vaccine makers may help sustain trust and access amid funding cuts.
• Comms teams face reputational, misinformation, and workload challenges.
• Key tactics: reach hesitant groups, support providers, manage info gaps.
• Industry can help fill roles left by weakened public programs

Also on April 2, Richard joins the closing keynote panel, "Rhetoric to Reality: New Administration’s Policies and the Vaccine Market." Topics include:

• Review each stage of the vaccine lifecycle: R&D, approval, manufacturing, distribution, and uptake.
• Analyze how new policies (e.g., agency changes, funding shifts, messaging) have disrupted these stages.
• Highlight political impacts on vaccine development and delivery.
• Aim to give stakeholders a clear, forward-looking view of the evolving vaccine market.

For more information, visit Terrapinn.com.